Fishman Jay A Ltd. MI Reduces Holdings in Johnson & Johnson $JNJ

Fishman Jay A Ltd. MI reduced its stake in Johnson & Johnson (NYSE:JNJ) by 15.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,906 shares of the company’s stock after selling 2,694 shares during the period. Fishman Jay A Ltd. MI’s holdings in Johnson & Johnson were worth $3,644,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blueline Advisors LLC bought a new stake in Johnson & Johnson in the 4th quarter worth $25,000. Cresta Advisors Ltd. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at about $26,000. DecisionPoint Financial LLC boosted its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the period. Semmax Financial Advisors Inc. grew its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the last quarter. Finally, Family CFO Inc bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $31,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.9%

NYSE JNJ opened at $258.48 on Friday. The firm has a market capitalization of $622.22 billion, a PE ratio of 29.88, a P/E/G ratio of 2.58 and a beta of 0.24. The stock’s 50 day moving average is $236.47 and its 200 day moving average is $232.88. Johnson & Johnson has a twelve month low of $154.80 and a twelve month high of $269.43. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts forecast that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a new ablation catheter platform that could strengthen its electrophysiology business and help drive future growth. Article Title
• Positive Sentiment: Jim Cramer said Johnson & Johnson “will have lots of good news” about its blockbuster drugs, adding to bullish sentiment around the stock. Article Title
• Positive Sentiment: Zacks highlighted JNJ’s strong earnings surprise history and said the company has the ingredients to beat estimates again in its next quarterly report, reinforcing confidence ahead of earnings. Article Title
• Positive Sentiment: TipRanks included Johnson & Johnson among Dividend Aristocrat stocks with a “Strong Buy” rating from top analysts, which may support demand for the shares. Article Title
• Neutral Sentiment: Several broader healthcare and market commentary pieces referenced JNJ as a defensive Dividend Aristocrat, but these were mostly general background items rather than company-specific catalysts. Article Title
• Negative Sentiment: Recent coverage also noted that JNJ had slipped in the prior session, suggesting some near-term profit-taking even as longer-term fundamentals remain intact. Article Title

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Guggenheim upped their price target on Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Royal Bank Of Canada restated an “outperform” rating and set a $265.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 15th. Barclays raised their price target on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 15th. Finally, Johnson Rice set a $270.00 price objective on shares of Johnson & Johnson in a research report on Friday, June 26th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $257.74.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.